The finding adds to a growing body of evidence that should give families pause before turning to CBD products, which are sold widely and often promoted with claims that far outrun the science behind them.

What the Trial Tested and What It Found

The double-blind, placebo-controlled trial, led by Dr. Daryl Efron of The Royal Children’s Hospital in Victoria, Australia, enrolled 132 youths ages 6 to 18 with intellectual disability and severe behavioral problems, including irritability, aggression, and self-injury. Participants received either CBD isolate in oil at 10 milligrams per kilogram daily or a placebo, taken orally for eight weeks.

The trial ran from May 2021 to May 2025 across three Australian children’s hospitals. Three-quarters of participants were male, the mean age was 11.2 years, and 87 percent were already taking at least one psychotropic medication when the study began.

The research team noted limitations of its own, including a fixed dose borrowed from pediatric epilepsy research, and acknowledged that smaller doses could theoretically behave differently.

Both groups improved, and that is the point. Scores on the parent-reported Aberrant Behavior Checklist irritability subscale fell from 32.2 to 21.7 in the CBD group and from 30.0 to 19.2 in the placebo group, a statistically insignificant difference of 2.4 points.

Rates of adverse events were nearly identical, at 63.1 percent for CBD and 60.6 percent for placebo, and CBD showed no advantage in any subgroup, including the 84 percent of participants diagnosed with autism spectrum disorder.

The results suggest that CBD should not be used to treat severe behavioral problems in this population.

A Pattern Across Multiple Studies

In an accompanying editorial, Dr. Adi Aran and Dr. Dalit Cayam-Rand of Shaare Zedek Medical Center in Jerusalem noted that the Australian results mirror a North American multicenter trial of youths with autism spectrum disorder, along with two additional trials that found no behavioral benefit from CBD. The lack of benefit, they wrote, extends across a broad range of cognitive abilities.

The editorialists also highlighted what the trials reveal about placebo response: parent-reported improvements were substantial even without the active compound, which is why uncontrolled studies and clinical anecdotes so often overstate what CBD can do.

What Families Should Take From This

CBD products sit on store shelves with little consistent oversight, and families facing severe behavioral challenges are exactly the audience most vulnerable to marketing built on hope.

The researchers did leave one door open: ongoing studies are evaluating CBD combined with other cannabis compounds such as terpenes and small amounts of THC, which could yet show different effects.

For now, the evidence points families toward established care. Behavioral therapy, psychiatric evaluation, and structured treatment programs have track records that CBD does not.

If your child is struggling with severe behavioral problems, a licensed treatment provider can assess what is driving the behavior and build a plan around approaches that have actually been tested.

Families sorting through treatment options for a child can start with a simple filter: ask any provider what evidence supports the approach being recommended, and be cautious of any product sold without it. Search Rehab.com’s directory to find treatment centers near you or call 800-985-8516 ( Question iconSponsored Helpline ) to speak with a treatment advisor.